Arrowhead pharmaceuticals, inc. (ARWR)
Income statement / Yearly
Sep'19Sep'18Sep'17Sep'16Sep'15Sep'14Sep'13Sep'12Sep'11Sep'10
REVENUE

168,795

16,142

31,407

158

382

175

290

146

296

-

OPERATING EXPENSES
Research and development

81,048

52,968

50,904

62,117

47,267

23,138

8,705

5,391

3,277

529

Acquired in-process research and development

-

-

-

-

10,142

-

-

-

-

-

Salaries and payroll-related costs

-

-

-

-

16,554

12,829

6,667

6,414

1,408

1,146

General and administrative expenses

26,556

19,110

17,499

23,594

7,931

5,894

3,488

6,439

3,795

2,490

Stock-based compensation

-

-

-

-

10,232

5,696

1,536

1,241

1,376

1,424

Depreciation and amortization

-

-

-

-

2,336

1,345

1,751

1,748

267

-

Impairment expense

-

-

-

2,050

-

2,172

1,308

-

-

-

Contingent consideration - fair value adjustments

-

-

-

-5,862

1,891

2,375

1,421

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

-

241

TOTAL OPERATING EXPENSES

107,604

72,078

68,403

81,901

96,355

53,451

24,879

21,236

10,126

5,832

OPERATING INCOME (LOSS)

61,190

-55,936

-36,995

-81,742

-95,973

-53,276

-24,589

-21,089

-9,830

-5,832

OTHER INCOME (EXPENSE)
Equity in income (loss) of unconsolidated affiliates

-

-

-

-

-

-78

-641

-240

-163

-219

Impairment on investment in unconsolidated affiliates

-

-

-

-

-

-

-

1,642

-

-

Gain on purchase of Roche Madison

-

-

-

-

-

-

-

1,576

-

-

Gain (loss) on sale of fixed asset, net

-

-

-

-

19

-58

-76

-1,079

-

1

Interest income (expense), net

6,957

1,048

415

265

729

645

-97

35

86

-22

Realized and unrealized gain (loss) in marketable securities

-

-

-

-

-

-

-

-58

-261

-

Change in value of derivatives

-

432

890

-301

2,869

-6,033

-5,300

386

1,133

1,761

Other income (expense)

-

7

1,312

57

417

82

-997

-

250

-

TOTAL OTHER INCOME (EXPENSE)

6,957

1,488

2,618

22

4,035

-5,443

-7,113

-1,021

1,045

1,520

INCOME (LOSS) BEFORE INCOME TAXES

68,148

-54,448

-34,377

-81,720

-91,938

-58,720

-31,703

-22,110

-8,785

-4,311

Provision for income taxes

173

2

2

2

2

5

-

-

0

0

LOSS FROM CONTINUING OPERATIONS

-

-

-

-

-

-

-31,703

-22,110

-8,785

-4,311

Loss from discontinued operations

-

-

-

-

-

-

-0

-

1,373

-2,645

Gain on disposal of discontinued operations

-

-

-

-

-

-

-

-

3,919

-

NET LOSS FROM DISCONTINUED OPERATIONS

-

-

-

-

-

-

-0

-0

5,292

-2,645

NET LOSS

-

-

-

-81,723

-91,940

-58,725

-31,703

-22,110

-3,492

-6,957

Net loss attributable to non-controlling interests

-

-

-

-

-

-95

-560

-984

-363

-1,182

NET INCOME (LOSS)

67,974

-54,450

-34,380

-

-

-58,630

-31,143

-21,125

-3,128

-5,774

NET LOSS PER SHARE - BASIC & DILUTED

-

-

-

-1.34

-1.60

-1.25

-1.30

-1.90

-

-

Loss from continuing operations attributable to Arrowhead common shareholders

-

-

-

-

-

-

-

-

-1.18

-0.49

Income from discontinued operations attributable to Arrowhead common shareholders

-

-

-

-

-

-

-

-

0.74

-0.41

NET INCOME (LOSS) PER SHARE - BASIC

0.72

-0.65

-0.47

-

-

-

-

-

-0.44

-0.90

Income (loss) from continuing operations attributable to Arrowhead common shareholders

-

-

-

-

-

-

-

-

-

-0.49

Income (loss) from discontinued operations attributable to Arrowhead common shareholders

-

-

-

-

-

-

-

-

-

-0.41

NET INCOME (LOSS) PER SHARE - DILUTED

0.69

-0.65

-0.47

-

-

-

-

-

-

-0.90

Weighted average shares outstanding - basic

93,858

83,638

73,898

-

-

-

-

-

7,181

6,434

Weighted average shares outstanding - diluted

98,607

83,638

73,898

-

-

-

-

-

-

6,434

Weighted average shares outstanding - basic and diluted

-

-

-

61,050

57,358

46,933

24,002

11,129

-

-

OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX:
Foreign currency translation adjustments

-370

-54

25

143

-136

-

-

-

-

-

COMPREHENSIVE INCOME (LOSS)

67,604

-54,505

-34,354

-81,579

-92,077

-58,630

-31,143

-

-

-